Lipocine Inc.·4

Dec 17, 4:06 PM ET

HILL STEPHEN A 4

4 · Lipocine Inc. · Filed Dec 17, 2020

Insider Transaction Report

Form 4
Period: 2020-12-16
Transactions
  • Exercise/Conversion

    Common Stock

    2020-12-16+7,50012,750 total
  • Exercise/Conversion

    Restricted Stock Unit

    2020-12-16+7,5007,500 total
    Exercise: $0.00From: 2020-12-16Exp: 2027-01-25Common Stock (7,500 underlying)
Footnotes (2)
  • [F1]Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units.
  • [F2]Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of TLANDO.

Documents

1 file
  • 4
    doc4_6961.xmlPrimary

    PRIMARY DOCUMENT